Augusta University has patented NSAID derivatives acting as prostaglandin G/H synthase 1 (PTGS1; COX-1) and/or COX-2 inhibitors potentially useful for the treatment of inflammation and pain.
Work at Duke University has led to the discovery of prodrugs of UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) (bacterial) inhibitors potentially useful for the treatment of cancer and gram-negative bacterial infections.
Researchers from China Pharmaceutical University published the design and preclinical characterization of novel potent and selective CDC2-like kinase 2 (CLK2) inhibitors as potential candidates for the treatment of osteoarthritis.
Researchers from Shenyang Pharmaceutical University and affiliated organizations have reported the identification of a selective cyclin-dependent kinase 9 (CDK9) inhibitor, CLZX-205, being developed for the treatment of colorectal cancer.
The FDA has cleared Prime Medicine Inc.’s IND application for PM-359 for the treatment of chronic granulomatous disease (CGD), enabling initiation of a phase I/II trial in the U.S.
Accession Therapeutics Ltd. has raised £25 million (US$31.3 million) to fund it through the generation of the first clinical data for its lead product, TROCEPT-01 (ATTR-01), and completion of IND-enabling studies for a second program. The internal early-stage pipeline will also be progressed.
The administration of a cross-reactive monoclonal antibody (MAb) protected hamsters and African green monkeys (AGM) several days after Nipah virus (NiV) infection.
Researchers from Longhorn Vaccines & Diagnostics LLC have presented data at the ongoing ESCMID conference regarding their unconjugated multiepitope vaccine against influenza, LHNVD-105.
Alligator Bioscience AB reported that Orion Corp. has selected the lead bispecific antibodies from the companies’ second development program, and is exercising its option to develop these molecules under the existing 2021 research collaboration and license agreement.
RSS
